QDEL
NASDAQQuidelOrtho Corporation
SectorHealth CareIndustryBiotechnology: In Vitro & In Vivo Diagnostic Substances
News · 26 weeks73-14%
2026-03-012026-08-23
Mix4190d
- Insider27(66%)
- Other7(17%)
- SEC Filings4(10%)
- Earnings2(5%)
- Leadership1(2%)
Latest news
25 items- INSIDEREVP Global Port. Mgmt & Mkting Hanson Bryan Michael covered exercise/tax liability with 162 shares and converted options into 446 shares, increasing direct ownership by 4% to 8,055 units (SEC Form 4) (withholding tax)4 - QuidelOrtho Corp (0001906324) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by QuidelOrtho CorporationSCHEDULE 13G/A - QuidelOrtho Corp (0001906324) (Subject)
- SECSEC Form SCHEDULE 13G filed by QuidelOrtho CorporationSCHEDULE 13G - QuidelOrtho Corp (0001906324) (Subject)
- SECQuidelOrtho Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - QuidelOrtho Corp (0001906324) (Filer)
- PRQuidelOrtho Reports Second Quarter 2026 Financial Results― Total revenue grew 3% reported and 2% constant currency, primarily driven by Labs and Point of Care growth ― ― Excluding China, total revenue grew 6% both as reported and in constant currency ― ― Company updates full-year 2026 financial guidance ― SAN DIEGO, Aug. 6, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a leading global provider of diagnostic solutions, today announced financial results for the second quarter ended June 28, 2026. Key Second Quarter 2026 Results:(all comparisons are to the prior year period)Total revenue was $631 million, an increase of 3% as reported and
- SECAmendment: SEC Form SCHEDULE 13G/A filed by QuidelOrtho CorporationSCHEDULE 13G/A - QuidelOrtho Corp (0001906324) (Subject)
- PRQuidelOrtho to Report Second Quarter 2026 Financial ResultsSAN DIEGO, July 24, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a leading global provider of diagnostic solutions, announced today that it will report its financial results for the second quarter 2026 ended June 28, 2026, after the market closes on Thursday, August 6, 2026. Following the release of financial results, QuidelOrtho will hold a conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET to discuss its financial results. Interested parties can access the call from the "Events & Presentations" section of the "Investor Relations" page of the Company's website at https://ir
- PRBeyond Fentanyl: How the Drug Crisis Is ChangingSAN DIEGO, July 23, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL), a global leader of in vitro diagnostics, has released episode 59 of its Science Bytes podcast examining how the drug overdose landscape continues to evolve and what laboratory and emergency department professionals need to know to support patient care. Based on new guidance from the Association for Diagnostics and Laboratory Medicine (ADLM), the episode explores the growing complexity of toxicology testing amid counterfeit medications, polysubstance use and emerging synthetic opioids. Hosted by Josh Casey, the episode features Vonda McAllister, Dire
- INSIDERSEC Form 4 filed by Chief Financial Officer Young Micah W4 - QuidelOrtho Corp (0001906324) (Issuer)
- PRQuidelOrtho Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, July 15, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL)("QuidelOrtho"), a leading global provider of diagnostic solutions, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of restricted stock units ("RSUs") with respect to 356,555 shares of the Company's common stock (the "Inducement Grant") to Micah Young, the Company's Chief Financial Officer and principal financial officer. The Inducement Grant was granted pursuant to the Company's 2026 Inducement Plan and as an inducement material to Mr. Young's entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
- INSIDERNew insider Young Micah W claimed no ownership of stock in the company (SEC Form 3)3 - QuidelOrtho Corp (0001906324) (Issuer)
- SECSEC Form S-8 filed by QuidelOrtho CorporationS-8 - QuidelOrtho Corp (0001906324) (Filer)
- SECSEC Form SCHEDULE 13G filed by QuidelOrtho CorporationSCHEDULE 13G - QuidelOrtho Corp (0001906324) (Subject)
- INSIDEREVP Global Port. Mgmt & Mkting Hanson Bryan Michael converted options into 5,797 shares and covered exercise/tax liability with 2,096 shares, increasing direct ownership by 91% to 7,771 units (SEC Form 4) to satisfy tax liability4 - QuidelOrtho Corp (0001906324) (Issuer)
- INSIDERSEC Form 4 filed by Director Widder Kenneth J4 - QuidelOrtho Corp (0001906324) (Issuer)
- INSIDERSEC Form 4 filed by Director Huennekens R Scott4 - QuidelOrtho Corp (0001906324) (Issuer)
- INSIDERSEC Form 4 filed by Director Chiminski John R4 - QuidelOrtho Corp (0001906324) (Issuer)
- INSIDERSEC Form 4 filed by Director Wilkins Joseph D Jr.4 - QuidelOrtho Corp (0001906324) (Issuer)
- INSIDERSEC Form 4 filed by Director Rhoads Ann D4 - QuidelOrtho Corp (0001906324) (Issuer)
- INSIDERSEC Form 4 filed by Director Polan Mary Lake Ph D4 - QuidelOrtho Corp (0001906324) (Issuer)
- INSIDERSEC Form 4 filed by Director Michael Edward L.4 - QuidelOrtho Corp (0001906324) (Issuer)
- INSIDERSEC Form 4 filed by Director Dilsaver Evelyn S4 - QuidelOrtho Corp (0001906324) (Issuer)
- INSIDERSEC Form 4 filed by Director Buechler Kenneth F4 - QuidelOrtho Corp (0001906324) (Issuer)
- SECQuidelOrtho Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - QuidelOrtho Corp (0001906324) (Filer)
- PRQuidelOrtho Appoints Micah Young as Chief Financial OfficerSeasoned medical technology finance executive brings more than two decades of leadership at global public companiesSAN DIEGO, June 23, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) ("QuidelOrtho" or the "Company"), a leading global provider of diagnostic solutions, today announced the appointment of Micah Young as Chief Financial Officer, effective July 6, 2026. Mr. Young will succeed Joseph M. Busky, who previously announced his retirement as Chief Financial Officer and will serve in an advisory role to support a smooth transition. "Micah is an accomplished public-company CFO with deep medical technology expertise
QDEL FAQ
6 questionsWhat does QuidelOrtho Corporation do?
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology worldwide. It offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a POC products to detect infectious and inflammatory diseases and conditions of the eye. The company also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes...Where does QDEL stock trade?
QuidelOrtho Corporation (QDEL) is listed on NASDAQ.What sector and industry is QDEL in?
QuidelOrtho Corporation operates in the Health Care sector, Biotechnology: In Vitro & In Vivo Diagnostic Substances industry.What are analysts saying about QDEL?
QuidelOrtho Corporation has had 8 recent analyst actions on file. The most recent action was from Jefferies: Hold with a $1250.00 price target on 2026-05-07. Recent price targets range from $1250.00 to $4400.00.What companies are similar to QDEL?
Notable peers in the same industry include IDXX (IDEXX Laboratories Inc.), ORKA (Oruka Therapeutics Inc.), LNTH (Lantheus Holdings Inc.), OCDX (Ortho Clinical Diagnostics Holdings plc), CLDX (Celldex Therapeutics Inc.). Compare QDEL side-by-side with any of them on Quantisnow.How can I track QDEL on Quantisnow?
Quantisnow aggregates QuidelOrtho Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow QDEL to receive live email and push alerts on every new disclosure.